|[July 16, 2014]
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014
SOUTH SAN FRANCISCO, Calif. --(Business Wire)--
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter
2014 financial results will be released on Thursday, July 31, 2014 after
the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management
will host a conference call to discuss the Company's financial results
for the second quarter 2014 and provide a general business update. The
conference call will be accessible via the Internet from the Company's
To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company's website at least 15 minutes prior to the
conference call to ensre adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
1-800-706-7745 (domestic) or 1-617-614-3472 (international) and provide
the conference call passcode 46301934 to join by phone.
A telephone replay will be available until 11:59 p.m. EDT on August 31,
2014. Access numbers for the telephone replay are: 888-286-8010
(domestic) and 617-801-6888 (international); the passcode is 25592695. A
webcast replay will also be archived on www.exelixis.com
for 30 days.
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple
receptor tyrosine kinases. Another Exelixis-discovered compound,
cobimetinib, a highly selective inhibitor of MEK, is being evaluated by
Roche and Genentech, Inc. (a member of the Roche Group) in a broad
development program under a collaboration with Exelixis. For more
information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
[ Back To TMCnet.com's Homepage ]